Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO21 Expert Video Report on targeting in HER2-positive metastatic breast and lung cancers

Reporting from the ESMO Congress 2021, Michail Ignatiadis discusses results from the DESTINY-Breast03 and DESTINY-Lung1 studies performed in the metastatic setting and testing the efficacy and safety of trastuzumab deruxtecan. He describes outstanding results in patients with HER2-positive tumours, with manageable toxicity, although the occurence of pneumonitis needs to be monitored, particularly in lung cancer patients.


  • LBA1 - Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer (mBC): Results of the Randomized, Phase 3 Study DESTINY-Breast03 - Dr Javier Cortés, ES
  • LBA45 - Primary Data from DESTINY-Lung01: A Phase 2 Trial of Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Mutated (HER2m) Metastatic Non-Small Cell Lung Cancer (NSCLC) - Dr Bob Li, US

This video was supported with an unrestricted grant from Bayer Healthcare
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.